Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLORead More
Persistent Pyelonephritis and Renal Abscess due to Mycoplasma hominis in an Immunocompromised Patient: A Case ReportRead More
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter AnalysisRead More
Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE studyRead More
Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman diseaseRead More
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialRead More
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemiaRead More
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analysesRead More
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with ImmunochemotherapyRead More
